Cosmo Pharmaceuticals N.V.

CMOPF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$153$2$24$24
Dep. & Amort.$12$14$14$7
Deferred Tax$0$0$0-$21
Stock-Based Comp.$2$4$2$1
Change in WC$0$1-$13-$5
Other Non-Cash-$5$2$6$6
Operating Cash Flow$162$23$33$13
Investing Activities
PP&E Inv.-$5-$3-$7-$9
Net Acquisitions$0$0$0$23
Inv. Purchases-$157-$61-$54-$1
Inv. Sales/Matur.$34$118$36$8
Other Inv. Act.-$1-$11$27$3
Investing Cash Flow-$129$42$2$25
Financing Activities
Debt Repay.-$1-$176-$1-$3
Stock Issued$3$1$0$1
Stock Repurch.-$6-$12-$25-$21
Dividends Paid-$32-$17-$16$0
Other Fin. Act.-$5-$7-$5-$5
Financing Cash Flow-$40-$211-$46-$27
Forex Effect$1-$0-$2$2
Net Chg. in Cash-$6-$136-$13$13
Supplemental Information
Beg. Cash$50$186$199$186
End Cash$44$50$186$199
Free Cash Flow$157$18$26$4
Cosmo Pharmaceuticals N.V. (CMOPF) Financial Statements & Key Stats | AlphaPilot